Astragalus Mongolians' Suppression of HBV DNA Level in ChronicHepatitis B (CHB) Patients with Moderately Increased AlanineAminotransferase (ALT)

Abstract

This paper aims to examine the impact of Astragalus on the quantity of HBV DNA in chronic hepatitis B (CHB) patients
with slightly raised ALT and the effect on IFN-G. Moreover, the work predicted that IFN-gamma would increase after
taking Astragalus Mongolians in CHB mouse patients with mildly raised ALT and effectively suppress the amount of
HBV DNA. Three groups of mice were set up, including a positive control group, a negative control group, and a group
of mice with mildly elevated ALT, which are more significant than one to two times the upper limit of normal (1-2 times
ULN) and carrying CHB. Astragalus was administered to mice previously infected with HBV in increasing doses and
for longer lengths of time. Entecavir was a positive control, while PBS + DMSO was the negative control. IFN-g in the
blood was detected using an ELISA test, and HBV DNA was determined using RT-PCR. The six possible results in this
paper correspond to the reaction of CHB-carrying mice with mildly elevated ALT to Astragalus. Whether the amount of
IFN-G and HBV DNA was elevated or reduced. The results of this paper will effectively predict the effect of Astragalus
on the amount of HBV DNA in CHB-carrying mice with mildly raised ALT with several different outcomes. This paper
also analyzes the different outcomes and compares the changes in IFN-G; corresponding conclusions will be drawn
based on the different outcomes.